Slides: Tailoring Prevention Strategies to What is Driving the MSM Epidemic

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > World AIDS Day 2005 > Buchbinder > Slides

Slides: Tailoring Prevention Strategies to What is Driving the MSM Epidemic

Susan Buchbinder, MD
December 1, 2005

Click on slide thumbnails to view full-sized image.

Download the entire set of PowerPoint slides

Slide 1.

Tailoring Prevention Strategies to What is Driving the MSM Epidemic

Slide 1.

Overview

Slide 2.

Spread of HIV in sub-Saharan Africa, 1987

Slide 3.

Spread of HIV in sub-Saharan Africa, 1997

Slide 4.

Estimated number of newly infected persons with HIV during 2005

Slide 5.

Spread of HIV in sub-Saharan Africa, 1997

Slide 6.

Prevalence of HIV in US MSM

Slide 7.

HIV Prevalence in South American Cities

Slide 8.

Estimated US HIV/AIDS diagnosed cases

Slide 9.

People living with AIDS in San Francsico

Slide 10.

Estimated US HIV/AIDS diagnosed cases

Slide 11.

People living with AIDS in San Francsico

Slide 12.

Unrecognized HIV Infection in US MSM

Slide 13.

Attributable risk

Slide 14.

Predictors of HIV seroconversion in MSM

Slide 15.

Predictors of HIV seroconversion in MSM

Slide 16.

Prevention approaches for MSM

Slide 17.

If behavior change were easy, I'd be thin

Slide 18.

The role of behavioral interventions

Slide 19.

Substance use

Slide 20.

Factors associated with unprotected serodiscordant anal sex

Slide 21.

Potential biological enhancement for HIV acquisition/transmission

Slide 22.

Project MIX

Slide 23.

Rectal microbicides

Slide 24.

Challenges in developing rectal microbicides

Slide 25.

Future directions in rectal microbicides

Slide 26.

Interventions unlinked from timing of risk behavior

Slide 27.

Calendar-based retrospective history on newly infected MSM

Slide 28.

HIV Vaccines

Slide 29.

HIV Vaccine Trials Network

Slide 30.

You can't get HIV from the vaccine

Slide 31.

MRKAd5 Trivalent Vaccine

Slide 32.

MRKAd5 trivalent gag/pol/nef at 3 x 1010

Slide 33.

SHIV Challenge of Ad5-SIV gag - Immunized Rhesus Monkeys

Slide 34.

STEP Study Overview

Slide 35.

Pre-Exposure Prophylaxis

Slide 36.

Using Antiretrovirals for Prevention in HIV Negatives

Slide 37.

Project T

Slide 38.

HSV-2 Suppression

Slide 39.

Overall and Subgroup Estimates of Risk of HSV-2 for HIV acquisition

Slide 40.

Population Attributable Risk Percentage of HIV Infection to HSV-2 Infection

Slide 41.

HIV prevention by suppressing HSV2

Slide 42.

You Don't Have To Have Sores To Have Genital Herpes

Slide 43.

Project Embrace

Slide 44.

Conclusions

Slide 45.

Acknowledgments

Slide 46.